natgillin/translations-raw huggingface dataset:
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 12,5 mg alogliptin (som benzoat) og 1.000 mg metforminhydrochlorid. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 1,000 mg metformin hydrochloride.
• problemer med leveren (hepatitis eller unormale leverfunktionstest). 
becoming breathless - Liver problems (hepatitis or liver function test abnormalities) - Erythema (redness of skin).
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 12,5 mg alogliptin (som benzoat) og 850 mg metforminhydrochlorid. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 850 mg metformin hydrochloride.
5.3) ved doser, som er ca. 5-20 gange højere (for henholdsvis metformin og alogliptin) end den humane eksponering ved den anbefalede dosis. 
Studies in pregnant rats with alogliptin plus metformin as combination treatment have shown reproductive toxicity (see section 5.3) at approximately 5-20 times (for metformin and alogliptin respectively) the human exposure at the recommended dose.
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/850 mg filmovertrukne tabletter Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter 
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1,000 mg film-coated tablets
Dosisjustering er ikke nødvendig på grund af alder. Der bør dog udvises forsigtighed ved doseringen af alogliptin til ældre patienter, da de har forhøjet risiko for nedsat nyrefunktion. 
However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population
Den gennemsnitlige ændring i fasteplasmaglucose fra baseline til uge 52 ved administration af 25 mg alogliptin plus 30 mg pioglitazon plus metformin var desuden signifikant større end den gennemsnitlige ændring, der blev registreret ved administration af 45 mg pioglitazon plus metformin (p<0,001). 
In addition, mean change from baseline in FPG at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p<0.001).
Patienterne skal informeres om at stoppe med at tage Vipdomet og øjeblikkeligt søge lægehjælp ved symptomer, der kan give mistanke om laktatacidose. 
In case of suspected symptoms, the patient should stop taking Vipdomet and seek immediate medical attention.
Alogliptin som tillæg til metformin sammen med et thiazolidindion Tillæg af 25 mg alogliptin én gang dagligt til pioglitazonbehandling (gennemsnitlig dosis = 35,0 mg, med eller uden metformin eller sulfonylurinstof) resulterede i statistisk signifikante forbedringer af HbA1c og fasteplasmaglucose i forhold til baseline i uge 26 sammenlignet med tillæg af placebo (tabel 2). 
Alogliptin as add-on therapy to metformin with a thiazolidinedione The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 2).
Alogliptin som tillæg til metformin sammen med insulin Tillæg af 25 mg alogliptin én gang dagligt til insulinbehandling (gennemsnitlig dosis = 56,5 IE, med eller uden metformin) resulterede i statistisk signifikante forbedringer af HbA1c og fasteplasmaglucose fra baseline til uge 26 sammenlignet med tillæg af placebo (tabel 2). 
Alogliptin as add-on therapy to metformin with insulin The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 2).
Det skal du vide, før du begynder at tage Vipdomet Sådan skal du tage Vipdomet Bivirkninger 
What Vipdomet is and what it is used for What you need to know before you take Vipdomet How to take Vipdomet
Flere af de patienter, der fik 25 mg alogliptin (7,8 %), nåede behandlingsmålet i uge 26 for HbA1c på ≤ 7,0 %, sammenlignet med de placebobehandlede patienter (0,8 %). 
More patients receiving 25 mg alogliptin (7.8%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (0.8%) at Week 26.
Signifikant flere patienter, der fik 25 mg alogliptin (44,4 %), nåede i uge 26 behandlingsmålet for HbA1c på ≤ 7,0 % sammenlignet med de placebobehandlede patienter (18,3 %) (p<0,001). 
Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (18.3%) at Week 26 (p<0.001).
- Hver 12,5 mg/850 mg filmovertrukken tablet indeholder alogliptinbenzoat svarende til 12,5 mg alogliptin og 850 mg metforminhydrochlorid. 
Each 12.5 mg/850 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 850 mg metformin hydrochloride.
- Hver 12,5 mg/1.000 mg filmovertrukken tablet indeholder alogliptinbenzoat svarende til 12,5 mg alogliptin og 1.000 mg metforminhydrochlorid. 
Each 12.5 mg/1,000 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 1,000 mg metformin hydrochloride.
svaghedsfornemmelse og stakåndethed. 
mood change or feeling confused.
- Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter (tabletter) er svagt gule, aflange (ca. 22,3 x 10,7 mm), bikonvekse filmovertrukne tabletter, der er præget med "12.5/1000" på den ene side og "322M" på den anden side. 
- Vipdomet 12.5 mg/1,000 mg film-coated tablets (tablets) are pale yellow, oblong (approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with “12.5/1000” debossed on one side and “322M” debossed on the other side.
Signifikant flere af de patienter, der fik 25 mg alogliptin (49,2 %), nåede behandlingsmålet i uge 26 (p=0,004) for HbA1c på ≤ 7,0 %, i forhold til de placebobehandlede patienter (34,0 %). 
Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).
Udseende og pakningsstørrelser - Vipdomet 12,5 mg/850 mg filmovertrukne tabletter (tabletter) er lysegule, aflange (ca. 21,0 x 10,1 mm), bikonvekse filmovertrukne tabletter, der er præget med "12.5/850" på den ene side og "322M" på den anden side. 
What Vipdomet looks like and contents of the pack - Vipdomet 12.5 mg/850 mg film-coated tablets (tablets) are light yellow, oblong (approximately 21.0 mm long by 10.1 mm wide), biconvex, film-coated tablets with “12.5/850” debossed on one side and “322M” debossed on the other side.
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/843/026 196 (2x98) filmovertrukne tabletter (multipakning) 
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 196 (2x98) film-coated tablets (multipack)
• nedsat B12-vitaminniveau eller anæmi. 
Very rare: - Decreased vitamin B12 levels or anaemia; symptoms include tiredness, lethargy, feeling faint,
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/843/025 196 (2x98) filmovertrukne tabletter (multipakning) 
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 196 (2x98) film-coated tablets (multipack)
• leverproblemer, der viser sig som kvalme, opkastning, mavesmerter, usædvanlig eller uforklarlig træthed, manglende appetit, mørkfarvet urin eller gulfarvning af huden eller det hvide i øjnene. 
loss of appetite, dark urine or yellowing of your skin or the whites of your eyes.
Gennem-snitlig ændring i HbA1c fra baseline (%)† (SE) 
Mean change from baseline in HbA1c (%)† (SE)
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/843/025 2x98 filmovertrukne tabletter 
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 2x98 film-coated tablets
Metabolisme og ernæring laktatacidose meget sjælden 
Hepatobiliary disorders hepatitis very rare
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/843/026 2x98 filmovertrukne tabletter 
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 2x98 film-coated tablets
Indlægsseddel: Information til patienten Vipdomet 12,5 mg/850 mg filmovertrukne tabletter Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter alogliptin/metforminhydrochlorid 
Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1000 mg film-coated tablets alogliptin/metformin hydrochloride
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/1.000 mg tabletter alogliptin/metforminhydrochlorid 
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/1,000 mg tablets alogliptin/metformin hydrochloride
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/850 mg tabletter alogliptin/metforminhydrochlorid 
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg tablets alogliptin/metformin hydrochloride
Hvis du har taget for meget Vipdomet 
If you take more Vipdomet than you should
Farmakoterapeutisk klassifikation: antidiabetika; komb. 
Pharmacotherapeutic group: Drugs used in diabetes; combinations of oral blood glucose lowering drugs.
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter alogliptin/metforminhydrochlorid 
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/1,000 mg film-coated tablets alogliptin/metformin hydrochloride
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/850 mg filmovertrukne tabletter alogliptin/metforminhydrochlorid 
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg film-coated tablets alogliptin/metformin hydrochloride
Behandlingskorrigeret ændring i HbA1c (%)† (en-sidet 
Treatment-corrected change from baseline in HbA1c (%)†
• forkølelsessymptomer som ondt i halsen, tilstoppet næse, træthed, feber, kulderystelser og tør hoste 
- Cold symptoms such as sore throat, stuffy or blocked nose, feeling tired, fever, chills, dry cough - Rash - Itchy skin with or without hives - Headache - Indigestion, heartburn - Vomiting and/or diarrhoea - Metallic taste.
Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter Svagt gule, aflange (ca. 22,3 mm lange og 10,7 mm brede), bikonvekse, filmovertrukne tabletter med "12.5/1000" præget på den ene side og "322M" på den anden side. 
Pale yellow, oblong (approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with “12.5/1000” debossed on one side and “322M” debossed on the other side.
6.1 eller en tidligere alvorlig overfølsomhedsreaktion, herunder anafylaktisk reaktion, anafylaktisk shock og angioødem, eller over for en dipeptidyl-peptidase-4 (DPP-4)-hæmmer (se pkt. 
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8) - Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis) - Diabetic pre-coma - Severe renal failure (GFR <30 mL/min) - Acute conditions with the potential to alter renal function such as: - dehydration - severe infection - shock - Acute or chronic disease which may cause tissue hypoxia (see section 4.4) such as: - cardiac or respiratory failure - recent myocardial infarction - shock - Hepatic impairment (see section 4.4) - Acute alcohol intoxication, alcoholism (see sections 4.4 and 4.5)
- mavesmerter 
Hepatic impairment
Vipdomet 12,5 mg/850 mg filmovertrukne tabletter Lysegule, aflange (ca. 21,0 mm lange og 10,1 mm brede), bikonvekse, filmovertrukne tabletter med "12.5/850" præget på den ene side og "322M" på den anden side. 
Light yellow, oblong (approximately 21.0 mm long by 10.1 mm wide), biconvex, film-coated tablets with “12.5/850” debossed on one side and “322M” debossed on the other side.
(%)† (SE) 
(1-sided CI)
• mavesmerter 
Lactic acidosis
Dette sammendrag blev sidst ajourført i 10-2008. 
This summary was last updated in October 2008.
Produktets tilbageholdelsestid er nul dage. 
The withdrawal period of the product is zero days.
I nogle tilfælde kan der opstå feber i én dag, og op til tre dage i sjældne tilfælde. 
In some cases fever may occur for one day, and up to three days in exceptional circumstances.
Alle undersøgelserne blev foretaget med Equilis Prequenza Te (kommentar: dobbelt; nævnt i næste afsnit). 
All studies were performed with Equilis Prequenza Te (comment: double; mentioned in next paragraph).
Herefter anbefales et maksimuminterval på to år. 
Afterwards, a maximum interval of two years is recommended.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Equilis Te til Intervet International BV den 8. juli 2005. 
The European Commission granted a marketing authorisation valid throughout the European Union, for Equilis Te to Intervet International BV on 8 July 2005.
Andre oplysninger om Equilis Te: 
Other information about Equilis Te:
Vaccinen gives som injektion i en muskel. 
The vaccine is given as an injection into a muscle.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Equilis Te. 
The Committee recommended that Equilis Te should be given a marketing authorisation.
Dette toksoid er et toksin, der er bearbejdet for at fjerne dets toksiske virkning, men bevare dets antigene egenskaber. 
The toxoid is a toxin processed in order to remove its toxic effect, but retain its antigenic properties.
diameter på 5 cm) kan forekomme ved injektionsstedet, enten som diffus hård eller blød hævelse. 
Swelling (max. diameter 5 cm) may occur at the injection site, either as diffuse hard or soft swelling.
Når heste vaccineres med produktet, hjælper det dyrets immunsystem til at reagere hurtigere, hvis dyret på naturlig vis skulle blive udsat for bakterien Clostridium tetani. 
When the product is given to horses, it helps the animals' immune system to react quicker when the animal is naturally exposed to the Clostridium tetani bacterium.
Vaccinen indeholder desuden et "adjuvans", der forstærker immunresponset. 
The vaccine also contains an ‘adjuvant' to stimulate a better immune response.
Der kan af og til opstå smerter ved injektionsstedet. 
Pain at the injection site can occur occasionally.
Virkningen af Equilis Te er blevet undersøgt i flere undersøgelser under laboratorie- og feltbetingelser. 
The effectiveness of Equilis Te has been studied in several trials under laboratory and field conditions.
Vaccinen findes som suspension til injektion. 
It is available as a suspension for injection.
Der blev ikke observeret nogen negativ indvirkning på svangerskabet, folingen eller afkommet blandt disse heste, efter at de var blevet vaccineret på forskellige tidspunkter under drægtigheden. 
No negative influence on gestation, foaling and offspring of mares was observed after vaccination at different times during pregnancy.
Den indeholder toksoid (kemisk inaktiveret toksin) fra tetanusbakterien. 
It contains the toxoid (chemically inactivated toxin) from the tetanus bacterium.
Stivkrampe er en akut, ofte dødelig sygdom, som skyldes et neurotoksin, der produceres af bakterien Clostridium tetani. 
Tetanus is an acute, often fatal disease caused by a neurotoxin produced by the bacterium Clostridium tetani.
For at beskyttelsen mod stivkrampe kan vare ved, skal hestene vaccineres igen. 
To retain protection against tetanus, horses need to be revaccinated.
Sikkerheden af Equilis Te blev undersøgt i adskillige undersøgelser under laboratorie- og feltbetingelser i et stort antal heste, fra tomånedersalderen og opefter. 
The safety of Equilis Te was studied in several studies under laboratory and field conditions in a large number of horses, from 2 months of age.
Den første revaccination bør finde sted senest 17 måneder efter basisvaccinationen. 
The first revaccination should be no later than 17 months after primary vaccination.
Varigheden af beskyttelse mod stivkrampe var 17 måneder efter basisvaccination og 24 måneder efter den første revaccination. 
The duration of protection against tetanus was 17 months after primary vaccination and 24 months after the first revaccination.
Hvilken risiko er der forbundet med Equilis Te? 
What is the risk associated with Equilis Te?
Hestene dannede beskyttelse to uger efter basisvaccination. 
Horses developed protection two weeks after primary vaccination.
Hvorfor blev Equilis Te godkendt? 
Why has Equilis Te been approved?
Equilis Te er en vaccine til heste. 
Equilis Te is a vaccine for use in horses.
Equilis Te er en vaccine indeholdende oprenset tetanustoksoid. 
Equilis Te is a vaccine containing purified tetanus toxoid.
Det primære effektmål var mængden af beskyttende antistoffer over for tetanustoksin efter vaccinationen. 
The main measure of effectiveness was the production of protective levels of antibodies against tetanus toxoid after vaccination.
Dette er med til at beskytte mod stivkrampe. 
This helps to protect against tetanus.
De fleste undersøgelser blev foretaget med Equilis Prequenza Te, en vaccine, der beskytter mod hesteinfluenza og mod stivkrampe. 
Most of the studies were performed with Equilis Prequenza Te, a vaccine that protects against equine influenza as well as against tetanus.
Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Equilis Te er større end risiciene til immunisering af heste, der er seks måneder gamle eller derover, mod stivkrampe for at forebygge dødelighed. 
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Equilis Te exceeded the risks for the immunisation of horses from six months of age against tetanus to prevent mortality.
Det blev konkluderet, at produktet tåles godt af heste med forskellig alder. Der blev også foretaget undersøgelser med drægtige hopper. 
It was concluded that the product is well tolerated by horses of different age.
Undersøgelserne viste, at Equilis Te er en effektiv vaccine mod stivkrampe for at forebygge dødelighed hos heste fra seks måneder og opefter. 
The studies showed that Equilis Te is an effective vaccine against tetanus to prevent mortality in horses from 6 months of age.
Hvordan blev Equilis Te undersøgt? 
How has Equilis Te been studied?
Equilis Te anvendes til vaccination af heste, fra de er seks måneder, mod tetanus (stivkrampe) for at forebygge dødelighed. 
Equilis Te is used to vaccinate horses from six months of age against tetanus to prevent mortality.
Heste er blandt de mest modtagelige arter over for stivkrampe. 
Horses belong to the most susceptible species to tetanus.
Hvilken fordel viser undersøgelserne, at der er ved Equilis Te? 
What benefit has Equilis Te shown during the studies?
Hvad anvendes Equilis Te til? 
What is Equilis Te used for?
Hvad er Equilis Te? 
What is Equilis Te?
Hvordan virker Equilis Te? 
How does Equilis Te work?
Den 9. december 2015 EMA/680058/2015 
09 December 2015 EMA/680058/2015
Lægemidler med friske blåbær bør kun anvendes til voksne og bør ikke tages længere end 4 uger. 
Fresh bilberry fruit medicines should only be used in adults and should not be taken for longer than 4 weeks.
HMPC har desuden vurderet kliniske undersøgelser af kredsløbsforstyrrelser, som er udført for 30-40 år siden. 
In its assessment, the HMPC also considered clinical studies on disorders of the circulatory system which were performed 30 - 40 years ago.
Hvis symptomerne vedvarer længere end 2 uger, bør der søges lægehjælp. 
If the symptoms persist for more than 2 weeks, a doctor or a qualified health care practitioner should be consulted.
Friske blåbær EMA/680058/2015 
Fresh bilberry fruit EMA/680058/2015
Friske blåbær er det almindelige navn for den friske frugt af planten Vaccinium myrtillus L. Tilberedninger af friske blåbær fås ved hjælp af en teknik til udtrækning af stoffer fra det friske plantemateriale ved opløsning i et opløsningsmiddel (såsom methanol), der derefter inddampes til en tør ekstrakt. 
Fresh bilberry fruit is the common name for the fresh fruit of the plant Vaccinium myrtillus L. Fresh bilberry fruit preparations are obtained using a technique to extract compounds from fresh plant material by dissolving them in a solvent (such as methanol), which is then evaporated to obtain a dry extract.
Anthocyaniner menes desuden at reparere ganske små blodkar efter skader på det lokale kredsløb. 
The anthocyanins are also thought to repair tiny blood vessels after damage to the local circulation.
Ansøgninger om godkendelse af lægemidler, der indeholder friske blåbær, skal indsendes til de nationale lægemiddelmyndigheder, som vurderer ansøgningen om plantelægemidlet og tager hensyn til HMPC's videnskabelige konklusioner. 
Any applications for the licensing of medicines containing fresh bilberry fruit have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Oplysninger om europæisk anvendelse og godkendelse af lægemidler, der indeholder friske blåbær, skal indhentes fra de relevante nationale myndigheder i EU's medlemsstater. 
Information on the use and licensing of fresh bilberry fruit medicines in EU Member States should be obtained from the relevant national authorities.
EU's medlemsstater tager hensyn til HMPC's konklusioner, når de vurderer ansøgninger om godkendelse af plantelægemidler, der indeholder friske blåbær. 
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing fresh bilberry fruit.
Dette dokument er et sammendrag af Udvalget for Plantelægemidlers (HMPC) videnskabelige konklusioner angående den medicinske anvendelse af friske blåbær. 
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of fresh bilberry fruit.
Detaljerede anvisninger på, hvordan lægemidler med friske blåbær skal anvendes, og hvem der kan bruge dem, findes i indlægssedlen i lægemiddelpakningen. 
Detailed instructions on how to take fresh bilberry fruit medicines and who can use them can be found in the package leaflet that comes with the medicine.
Friske blåbær 
Fresh bilberry fruit
Dette sammendrag er ikke en praktisk vejledning i, hvordan plantelægemidler, der indeholder friske blåbær, skal anvendes. 
This summary is not intended to provide practical advice on how to use medicines containing fresh bilberry fruit.
Hvad er friske blåbær? 
What is fresh bilberry fruit?
Plantelægemidler med tilberedninger af friske blåbær fås normalt i fast form til anvendelse gennem munden. 
Herbal medicines containing fresh bilberry fruit preparations are usually available in solid forms to be taken by mouth.
Andre oplysninger om lægemidler, der indeholder friske blåbær 
Other information about fresh bilberry fruit medicines
Hvordan godkendes lægemidler, der indeholder friske blåbær, i EU? 
How are fresh bilberry fruit medicines approved in the EU?
Laboratorieundersøgelser viser, at blåbær er rige på anthocyaniner, som menes at forbedre kredsløbet ved at afslappe og udvide blodkarrene og beskytte dem mod skade. 
Results from laboratory studies indicate that bilberries are rich in anthocyanins, which are thought to improve blood circulation by relaxing and dilating (widening) blood vessels and protecting blood vessels from damage.
HMPC's konklusioner vedrørende anvendelsen af lægemidler med friske blåbær til lindring af ubehag og tyngdefornemmelse i benene forbundet med mindre kredsløbsproblemer og til lindring af symptomer på blødning i huden fra små blodkar er baseret på lægemidlernes "traditionelle anvendelse". 
The HMPC conclusions on the use of fresh bilberry fruit medicines for relief of discomfort and heaviness of legs related to minor blood circulatory problems and for relief of symptoms of bleeding into the skin from tiny blood vessels are based on their ‘traditional use'.
Hvilke risici er der forbundet med lægemidler, der indeholder friske blåbær? 
What are the risks associated with fresh bilberry fruit medicines?
Hvilken dokumentation underbygger den medicinske anvendelse af friske blåbær? 
What evidence supports the use of fresh bilberry fruit medicines?